Trial reportTranslational psychiatry2021
Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial.
Trial report in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [European journal of nuclear medicine and molecular imaging · 2023Pooled it
- Systematic review and meta-analysis on the therapeutic reference range for escitalopram: Blood concentrations, clinical effects and serotonin transporter occupancy.Frontiers in psychiatry · 2022Pooled it
- Impressions about harm are formed rapidly and then refined, modulated by serotonin.Social cognitive and affective neuroscience · 2024Trial
- Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression.Psychological medicine · 2024Trial
- Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy.Translational psychiatry · 2022Trial
- Social anxiety and the positive valence system: A scoping review.Journal of mood and anxiety disorders · 2026Review
- Accelerated recovery using magnesium ibogaine: characterizing the subjective experience of its rapid healing from neuropsychiatric disorders.Npj mental health research · 2026Article
- Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis.Frontiers in psychiatry · 2026Article
- Investigating the dose-response relationship between music and anxiety reduction: A randomized clinical trial.PLOS mental health · 2026Article
- Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials.JAMA psychiatry · 2025Review
- Revisiting the SSRI vs. placebo debate in the treatment of social anxiety disorder: the role of expectancy effects, neural responsivity, and monoamine transporters.Frontiers in psychology · 2025Article
- Dispositional Optimism Predicts Antidepressant Treatment Response in Major Depressive Disorder: Potential Relevance for Positive Psychology Interventions.The journal of positive psychology · 2024Article
- Electroacupuncture alleviated depression-like behaviors in ventromedial prefrontal cortex of chronic unpredictable mild stress-induced rats: Increasing synaptic transmission and phosphorylating dopamine transporter.CNS neuroscience & therapeutics · 2023Article
- Dopamine, Immunity, and Disease.Pharmacological reviews · 2023Review
- Serotonin-related Mechanisms in the Etiology and Pharmacotherapy of Social Phobia, A Review.Galen medical journal · 2023Review
- Demographic characteristics and anxiety in the educational setting during the COVID-19 pandemic in Indonesia: A cross-sectional study.Health science reports · 2022Article
- Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.Journal of psychopharmacology (Oxford, England) · 2022Article
- Application of positron emission tomography in psychiatry-methodological developments and future directions.Translational psychiatry · 2022Review
- Structural and functional deficits and couplings in the cortico-striato-thalamo-cerebellar circuitry in social anxiety disorder.Translational psychiatry · 2022Article
- Horizons in Human Aging Neuroscience: From Normal Neural Aging to Mental (Fr)Agility.Frontiers in human neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been extensively debated whether selective serotonin reuptake inhibitors (SSRIs) are more efficacious than placebo in affective disorders, and it is not fully understood how SSRIs exert their beneficial effects. Along with serotonin transporter blockade, altered dopamine signaling and psychological factors may contribute. In this randomized clinical trial of participants with social anxiety disorder (SAD) we investigated how manipulation of verbally-induced expectancies, vital for placebo response, affect brain monoamine transporters and symptom improvement during SSRI treatment. Twenty-seven participants with SAD (17 men, 10 women), were randomized, to 9 weeks of overt or covert treatment with escitalopram 20 mg. The overt group received correct treatment information whereas the covert group was treated deceptively with escitalopram, described as an active placebo in a cover story. Before and after treatment, patients underwent positron emission tomography (PET) assessments with the [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.